{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:51:52Z","timestamp":1783687912187,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020595","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST108-2314-B-038-104-MY3"],"award-info":[{"award-number":["MOST108-2314-B-038-104-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022600","name":"Wan Fang Hospital","doi-asserted-by":"publisher","award":["111TMU-WFH-04"],"award-info":[{"award-number":["111TMU-WFH-04"]}],"id":[{"id":"10.13039\/501100022600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.intimp.2023.110473","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T05:41:47Z","timestamp":1686894107000},"page":"110473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Norisoboldine exerts antiallergic effects on IgE\/ovalbumin-induced allergic asthma and attenuates Fc\u03b5RI-mediated mast cell activation"],"prefix":"10.1016","volume":"121","author":[{"given":"Jer-Hwa","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Chi","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Kwung","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Yun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueh-Lun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.110473_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104296","article-title":"Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers","volume":"146","author":"Santus","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2023.110473_b0010","first-page":"118","article-title":"Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes","volume":"36","author":"Gans","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2023.110473_b0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-021-08894-x","article-title":"Different phenotypes in asthma: Clinical findings and experimental animal models","volume":"62","author":"Lourenco","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110473_b0020","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41577-021-00622-y","article-title":"Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases","volume":"22","author":"Kolkhir","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110473_b0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.110473_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101333","article-title":"Immunologic mechanisms in asthma","volume":"46","author":"Boonpiyathad","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2023.110473_b0035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3389\/fimmu.2019.00821","article-title":"Mast cells and their progenitors in allergic asthma","volume":"10","author":"Mendez-Enriquez","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110473_b0040","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12016-018-8720-1","article-title":"Mast cell-mediated orchestration of the immune responses in human allergic asthma: Current insights","volume":"56","author":"Elieh Ali Komi","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110473_b0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12634","article-title":"Mast cells as sources of cytokines, chemokines, and growth factors","volume":"282","author":"Mukai","year":"2018","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2023.110473_b0050","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1080\/21655979.2022.2044278","article-title":"The role of human mast cells in allergy and asthma","volume":"13","author":"Banafea","year":"2022","journal-title":"Bioengineered"},{"issue":"6","key":"10.1016\/j.intimp.2023.110473_b0055","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00281-019-00770-3","article-title":"Resolution of allergic asthma","volume":"41","author":"Finotto","year":"2019","journal-title":"Semin. Immunopathol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110473_b0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10753-010-9197-0","article-title":"Norisoboldine inhibits the production of pro-inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 cells by down-regulating the activation of MAPKs but not NF-kappaB","volume":"33","author":"Luo","year":"2010","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.intimp.2023.110473_b0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/aps.2012.187","article-title":"Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE(2), and MMP-13 expression","volume":"34","author":"Wei","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.intimp.2023.110473_b0070","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/08923973.2016.1202961","article-title":"Norisoboldine, an alkaloid from Radix linderae, inhibits NFAT activation and attenuates 2,4-dinitrofluorobenzene-induced dermatitis in mice","volume":"38","author":"Gao","year":"2016","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110473_b0075","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.intimp.2015.08.040","article-title":"Norisoboldine ameliorates DSS-induced ulcerative colitis in mice through induction of regulatory T cells in colons","volume":"29","author":"Lv","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110473_b0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.taap.2014.11.008","article-title":"Norisoboldine ameliorates collagen-induced arthritis through regulating the balance between Th17 and regulatory T cells in gut-associated lymphoid tissues","volume":"282","author":"Tong","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110473_b0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biocel.2016.03.014","article-title":"Norisoboldine, an isoquinoline alkaloid, acts as an aryl hydrocarbon receptor ligand to induce intestinal Treg cells and thereby attenuate arthritis","volume":"75","author":"Tong","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110473_b0090","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41419-018-0297-3","article-title":"Norisoboldine, a natural AhR agonist, promotes Treg differentiation and attenuates colitis via targeting glycolysis and subsequent NAD(+)\/SIRT1\/SUV39H1\/H3K9me3 signaling pathway","volume":"9","author":"Lv","year":"2018","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.intimp.2023.110473_b0095","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/gt.2010.39","article-title":"Cytokine gene-modulated dendritic cells protect against allergic airway inflammation by inducing IL-10(+)IFN-gamma(+)CD4(+) T cells","volume":"17","author":"Hsu","year":"2010","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.intimp.2023.110473_b0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.intimp.2014.12.027","article-title":"Zerumbone enhances the Th1 response and ameliorates ovalbumin-induced Th2 responses and airway inflammation in mice","volume":"24","author":"Shieh","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.110473_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107782","article-title":"Catalpol exerts antiallergic effects in IgE\/ovalbumin-activated mast cells and a murine model of ovalbumin-induced allergic asthma","volume":"96","author":"Chiu","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110473_b0110","doi-asserted-by":"crossref","first-page":"11895","DOI":"10.1038\/s41598-017-12252-3","article-title":"Polydatin inhibits mast cell-mediated allergic inflammation by targeting PI3K\/Akt, MAPK, NF-kappaB and Nrf2\/HO-1 pathways","volume":"7","author":"Ye","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.110473_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108953","article-title":"Neobavaisoflavone inhibits allergic inflammatory responses by suppressing mast cell activation","volume":"110","author":"Liang","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110473_b0120","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1248\/bpb.b21-00457","article-title":"Norisoboldine attenuates sepsis-induced acute lung injury by modulating macrophage polarization via PKM2\/HIF-1alpha\/PGC-1alpha pathway","volume":"44","author":"Chen","year":"2021","journal-title":"Biol. Pharm. Bull."},{"issue":"10","key":"10.1016\/j.intimp.2023.110473_b0125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.phymed.2010.01.013","article-title":"Therapeutic effect of norisoboldine, an alkaloid isolated from Radix Linderae, on collagen-induced arthritis in mice","volume":"17","author":"Luo","year":"2010","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.intimp.2023.110473_b0130","doi-asserted-by":"crossref","first-page":"e22937","DOI":"10.1002\/jbt.22937","article-title":"The protective effects of propofol against renal ischemia-reperfusion injury are potentiated by norisoboldine treatment via inhibition of oxidative stress pathways","volume":"36","author":"Xing","year":"2022","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110473_b0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/15376516.2019.1669242","article-title":"Application of a DSS colitis model in toxicologically assessing norisoboldine","volume":"30","author":"Huang","year":"2020","journal-title":"Toxicol. Mech. Methods"},{"issue":"5","key":"10.1016\/j.intimp.2023.110473_b0140","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1164\/ajrccm.151.5.7735584","article-title":"Circulating interleukin-6 levels in patients with bronchial asthma","volume":"151","author":"Yokoyama","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.110473_b0145","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.159.2.9805115","article-title":"Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus","volume":"159","author":"Tillie-Leblond","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.110473_b0150","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.4049\/jimmunol.0802923","article-title":"IL-6 is required for airway mucus production induced by inhaled fungal allergens","volume":"183","author":"Neveu","year":"2009","journal-title":"J. Immunol."},{"issue":"6469","key":"10.1016\/j.intimp.2023.110473_b0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/368339a0","article-title":"Impaired immune and acute-phase responses in interleukin-6-deficient mice","volume":"368","author":"Kopf","year":"1994","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.intimp.2023.110473_b0160","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.4049\/jimmunol.165.7.4051","article-title":"Endogenous and exogenous IL-6 inhibit aeroallergen-induced Th2 inflammation","volume":"165","author":"Wang","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.110473_b0165","doi-asserted-by":"crossref","unstructured":"Z. Jevnikar, J. Ostling, E. Ax, J. Calven, K. Thorn, E. Israelsson, L. Oberg, A. Singhania, L.C.K. Lau, S.J. Wilson, J.A. Ward, A. Chauhan, A.R. Sousa, B. De Meulder, M.J. Loza, F. Baribaud, P.J. Sterk, K.F. Chung, K. Sun, Y. Guo, I.M. Adcock, D. Payne, B. Dahlen, P. Chanez, D.E. Shaw, N. Krug, J.M. Hohlfeld, T. Sandstrom, R. Djukanovic, A. James, T.S.C. Hinks, P.H. Howarth, O. Vaarala, M. van Geest, H. Olsson, g. Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes study. (2019) Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. J Allergy Clin Immunol; 143(2):577-590. http:\/\/doi.org\/10.1016\/j.jaci.2018.05.026.","DOI":"10.1016\/j.jaci.2018.05.026"},{"issue":"2","key":"10.1016\/j.intimp.2023.110473_b0170","doi-asserted-by":"crossref","first-page":"e24333","DOI":"10.4161\/tisb.24333","article-title":"Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells","volume":"1","author":"Saatian","year":"2013","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.intimp.2023.110473_b0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-019-0079-0","article-title":"Targeting cell signaling in allergic asthma","volume":"4","author":"Athari","year":"2019","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.110473_b0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MCP.0000000000000224","article-title":"Airway inflammation in asthma: key players beyond the Th2 pathway","volume":"22","author":"KleinJan","year":"2016","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"10","key":"10.1016\/j.intimp.2023.110473_b0185","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.4049\/jimmunol.172.10.6398","article-title":"Mast cells, Fc epsilon RI, and IL-13 are required for development of airway hyperresponsiveness after aerosolized allergen exposure in the absence of adjuvant","volume":"172","author":"Taube","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.110473_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.912529","article-title":"Current strategies to modulate regulatory T cell activity in allergic inflammation","volume":"13","author":"Bellinghausen","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110473_b0195","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12967-020-02632-1","article-title":"Regulatory T cells mediated immunomodulation during asthma: a therapeutic standpoint","volume":"18","author":"Khan","year":"2020","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.intimp.2023.110473_b0200","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/eji.202048909","article-title":"Prostaglandin regulation of type 2 inflammation: From basic biology to therapeutic interventions","volume":"51","author":"Oyesola","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110473_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103036","article-title":"Prostaglandin D(2) induces Ca(2+) sensitization of contraction without affecting cytosolic Ca(2+) level in bronchial smooth muscle","volume":"19","author":"Suto","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.110473_b0210","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.168.1.443","article-title":"Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice","volume":"168","author":"Fujitani","year":"2002","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110473_b0215","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.20022218","article-title":"Prostaglandin D2 reinforces Th2 type inflammatory responses of airways to low-dose antigen through bronchial expression of macrophage-derived chemokine","volume":"198","author":"Honda","year":"2003","journal-title":"J. Exp. Med."},{"issue":"38","key":"10.1016\/j.intimp.2023.110473_b0220","doi-asserted-by":"crossref","first-page":"32891","DOI":"10.1074\/jbc.R110.205104","article-title":"Immunoglobulin E receptor signaling and asthma","volume":"286","author":"Wu","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2023.110473_b0225","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ar.24506","article-title":"Isorhamnetin attenuates TNF-alpha-induced inflammation, proliferation, and migration in human bronchial epithelial cells via MAPK and NF-kappaB pathways","volume":"304","author":"Ren","year":"2021","journal-title":"Anat. Rec. (Hoboken)"},{"issue":"4","key":"10.1016\/j.intimp.2023.110473_b0230","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1183\/09031936.00058907","article-title":"Mast cell-derived tumour necrosis factor is essential for allergic airway disease","volume":"31","author":"Reuter","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.intimp.2023.110473_b0235","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaci.2007.02.046","article-title":"Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice","volume":"120","author":"Nakae","year":"2007","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923007968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923007968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:09:52Z","timestamp":1761588592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923007968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":47,"alternative-id":["S1567576923007968"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110473","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Norisoboldine exerts antiallergic effects on IgE\/ovalbumin-induced allergic asthma and attenuates Fc\u03b5RI-mediated mast cell activation","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110473"}}